What is Acurion?
Acurion operates at the intersection of computational pathology and oncology, providing a scalable alternative to traditional, resource-intensive genomic testing. The company's core technology, OncoGaze, utilizes advanced image analysis to identify biomarkers directly from standard clinical pathology slides. This approach effectively bypasses the need for additional tissue samples or specialized molecular assays, which are often associated with significant testing delays and high costs. By integrating seamlessly into existing clinical workflows, Acurion is democratizing access to precision medicine, ensuring that patients across diverse cancer types receive timely, data-driven treatment recommendations. The firm's market position is defined by its ability to transform conventional diagnostic data into high-value clinical intelligence, thereby enhancing the standard of care in oncology.
How much funding has Acurion raised?
Acurion has raised a total of $4.3M across 1 funding round:
Seed
$4.3M
Seed (2026): $4.3M with participation from National Foundation for Cancer Research, Mesa Verde, and Asian Fund for Cancer Research
Key Investors in Acurion
National Foundation for Cancer Research
A nonprofit organization dedicated to funding innovative cancer research aimed at finding cures for all types of cancer through groundbreaking discoveries in treatment and detection.
Mesa Verde
An early-stage life sciences venture capital firm based in San Diego, focusing on biomedical companies, diagnostics, and digital health innovations.
Asian Fund for Cancer Research
A research-focused organization dedicated to supporting innovative cancer studies and global collaborations, with a specific emphasis on cancers prevalent in Asian populations.
What's next for Acurion?
With this major enterprise-level funding, Acurion is poised to accelerate the commercial deployment of its OncoGaze platform and expand its clinical validation studies. The strategic roadmap focuses on broadening the utility of its AI-powered tools across a wider spectrum of advanced cancer types, aiming to reduce the time-to-treatment for patients globally. Furthermore, the company is expected to invest in strengthening its regulatory footprint and enhancing its diagnostic algorithms to maintain a competitive edge in the rapidly evolving digital health landscape. As the industry shifts toward more accessible and rapid diagnostic solutions, Acurion's focus on leveraging existing clinical infrastructure positions it as a key player in the future of personalized cancer care.
See full Acurion company page
